search
Back to results

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

Primary Purpose

Cocaine-Related Disorders

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
National Institute on Drug Abuse (NIDA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Cocaine-Related Disorders focused on measuring cocaine dependence

Eligibility Criteria

21 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: opiate experienced, healthy Exclusion Criteria: physical dependence on opioids, barbiturates or alcohol

Sites / Locations

  • Johns Hopkins University (BPRU) Bayview Campus

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 20, 1999
Last Updated
January 11, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00000323
Brief Title
Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
Official Title
Therapeutic Potential of Kappa-Opioids Against Cocaine
Study Type
Observational

2. Study Status

Record Verification Date
May 2004
Overall Recruitment Status
Completed
Study Start Date
July 1996 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 1998 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Drug Abuse (NIDA)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders
Keywords
cocaine dependence

7. Study Design

Enrollment
10 (false)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: opiate experienced, healthy Exclusion Criteria: physical dependence on opioids, barbiturates or alcohol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sharon Walsh, Ph.D.
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins University (BPRU) Bayview Campus
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224 6823
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11594439
Citation
Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001 Sep;157(2):151-62. doi: 10.1007/s002130100788.
Results Reference
background

Learn more about this trial

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

We'll reach out to this number within 24 hrs